Immunohistochemistry-Frozen: Collagen VI alpha 1 Antibody [NB120-6588] - Feline blood vessels section. The image was captured with an epifluorescent microscope. Image submitted by a verified customer review
Immunohistochemistry: Collagen VI alpha 1 Antibody [NB120-6588] - Showed strong staining in FFPE sections of human placenta (Left) with red staining of stromal and extracellular spaces, and in testis (Right) with ...read more
Collagen Type VI from human and bovine placenta. Uniprot ID P12109
Negligible cross-reactivity with Type I, II, III, IV or V collagens. Non-specific cross reaction of anti-collagen antibodies with other human serum proteins or non-collagen extracellular matrix proteins is negligible.
Immunogen affinity purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Anti-Collagen antibodies have been used for indirect trapping ELISA for quantitation of antigen in serum using a standard curve, for immunoprecipitation and for native PAGE and western blotting for highly sensitive qualitative analysis. Greatly diminished reactivity and selectivity of these antibodies will result if denaturing and reducing conditions are used for in immunoblotting. Use in ICC/IF reported in scientific literature (PMID 24378017). Use in FLOW cytometry reported in scientific literature ( PMID 25774777). Collagen VI alpha 1 antibody validated for IHC-F from a verified customer review. Use in PCR reported in secitific publication PMID: 32719790
This antibody reacts with most mammalian Type VI collagens and has negligible cross-reactivity with Type I, II, III, IV and V collagens. Non-specific cross reactivity of anti-collagen antibodies with other human serum proteins or non-collagen extracellular matrix proteins is negligible.
Packaging, Storage & Formulations
Store at 4C short term. For extended storage, add an equal volume of glycerol, aliquot and store at -20C or below. Avoid repeated freeze-thaw cycles.
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
0.01% Sodium Azide
Immunogen affinity purified
Alternate Names for Collagen VI alpha 1 Antibody
collagen alpha-1(VI) chain
collagen VI, alpha-1 polypeptide
collagen, type VI, alpha 1
human mRNA for collagen VI alpha-1 C-terminal globular domain10alpha 1 (VI) chain (61 AA)
This antibody is well suited to detect extracellular matrix proteins in normal as well as disease state tissues. Disruption of tissue organization is the hallmark of neoplasia. Malignant lesions can be distinguished from benign by examining the breakdown of basement membranes and loss of 3-dimensional architecture. Malignant cells are presumed to use matrix metalloproteases to degrade barriers created by the extracellular matrix which then allows metastasis to occur. Collagenases, stomelysins and gelatinases can collectively degrade all of the various components of the extracellular matrix, including fibrillar and non-fibrillar collagens and basement membrane glycoproteins.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.